B+
Bull case
25%
Probability
Target price
$1.10
+87.7% vs current
NXGL
NexGelBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.65
+10.9% vs current
B-
Bear case
30%
Probability
Target price
$0.25
-57.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+56.6
Score
AI commentary
Tentative lean-positive monitoring view only. The hard evidence improved with 2025 revenue growth to $11.4 million and better gross profit, yet the filing also shows substantial doubt about the company's ability to continue as a going concern and very limited unrestricted cash [#10-K-2026-03-31]. The March 2026 Celularity deal is the only clearly transformational upside driver in hand, but it is still financing-dependent and therefore not reliable enough to support a stronger thesis for a low-coverage micro-cap name [#8-K-2026-03-10].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-05-15catalystNext quarterly filing should clarify liquidity and deal statusHigh impact
NexGel ended 2025 with only $317 thousand of unrestricted cash, $741 thousand of restricted cash, and management disclosed substantial doubt about continuing as a going concern, so the next quarterly filing should be a high-signal checkpoint on financing progress, dilution, and whether the Celularity transaction is still executable [#10-K-2026-03-31] [#8-K-2026-03-10].
2026-06-30eventCelularity asset deal financing and closing updateHigh impact
The March 6, 2026 asset purchase and exclusive license agreement requires financing sufficient to fund the $15.0 million upfront payment, and management separately said it expected about $14.9 million of additional financing in late Q1 or early Q2 2026; a close, delay, or termination would likely drive the next major re-rate because the deal is framed as transformative [#8-K-2026-03-10].
2026-12-31catalystIf the Celularity portfolio closes, integration could reset the revenue baseHigh impact
Company materials say the acquired regenerative biomaterials portfolio could approximately triple annual revenue to about $35 million, add reimbursed commercial-stage products, and make NexGel profitable immediately upon closing; if those claims begin to show up in reported results, the stock could re-rate sharply from its current micro-cap base, but this remains contingent on financing and execution [#8-K-2026-03-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology